Total Payments
$682.12
2024 Payments
$215.16
Companies
18
Transactions
41
Medicare Patients
1,955
Medicare Billing
$121,895
Payment Breakdown by Category
Food & Beverage$682.12 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $682.12 | 41 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $234.22 | 12 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $65.36 | 3 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $56.63 | 4 | $0 (2022) |
| GlaxoSmithKline, LLC. | $46.89 | 3 | $0 (2024) |
| Merck Sharp & Dohme LLC | $35.14 | 2 | $0 (2022) |
| PFIZER INC. | $31.18 | 2 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $27.70 | 3 | $0 (2021) |
| Lilly USA, LLC | $24.56 | 2 | $0 (2021) |
| Axsome Therapeutics, Inc. | $19.74 | 1 | $0 (2024) |
| Novo Nordisk Inc | $17.65 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $215.16 | 12 | ABBVIE INC. ($56.62) |
| 2023 | $113.25 | 6 | ABBVIE INC. ($83.13) |
| 2022 | $112.62 | 6 | ABBVIE INC. ($45.52) |
| 2021 | $241.09 | 17 | AbbVie Inc. ($48.95) |
All Payment Transactions
41 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/05/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 12/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: Cardio-renal | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: VACCINES | ||||||
| 10/17/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: Inflammation | ||||||
| 10/10/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: RESPIRATORY | ||||||
| 09/26/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 08/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: NEUROSCIENCE | ||||||
| 07/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: NEUROSCIENCE | ||||||
| 06/03/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/04/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: Psychology/Psychiatric | ||||||
| 01/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: NEUROSCIENCE | ||||||
| 10/23/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: NEUROSCIENCE | ||||||
| 10/10/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: NEUROSCIENCE | ||||||
| 08/07/2023 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $14.55 | General |
| Category: PSYCHIATRY | ||||||
| 07/17/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: NEUROSCIENCE | ||||||
| 04/24/2023 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: Diabetes | ||||||
| 02/27/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.12 | General |
| Category: NEUROSCIENCE | ||||||
| 09/12/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: DIABETES | ||||||
| 08/15/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.74 | General |
| Category: NEUROSCIENCE | ||||||
| 06/13/2022 | Merck Sharp & Dohme LLC | BELSOMRA (Drug), STEGLUJAN, STEGLATRO | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: NEUROSCIENCE | ||||||
| 04/25/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), SYNJARDY | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: DIABETES | ||||||
| 04/04/2022 | Merck Sharp & Dohme LLC | BELSOMRA (Drug), STEGLUJAN, STEGLATRO | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: NEUROSCIENCE | ||||||
| 03/28/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.47 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 416 | 826 | $71,864 | $24,907 |
| 2022 | 12 | 578 | 865 | $97,335 | $36,992 |
| 2021 | 11 | 506 | 929 | $88,538 | $32,643 |
| 2020 | 11 | 455 | 848 | $83,563 | $27,353 |
Total Patients
1,955
Total Services
3,468
Medicare Billing
$121,895
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 126 | 258 | $38,654 | $11,665 | 30.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 60 | 60 | $11,460 | $6,250 | 54.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 56 | $11,854 | $3,571 | 30.1% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 15 | 15 | $1,515 | $1,007 | 66.5% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 18 | 19 | $2,158 | $832.08 | 38.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 63 | 89 | $1,280 | $741.34 | 57.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 17 | 17 | $323.00 | $316.54 | 98.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 24 | 44 | $1,760 | $309.33 | 17.6% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 13 | 156 | $468.00 | $106.17 | 22.7% |
| 81003 | Automated urinalysis test | Office | 2023 | 26 | 40 | $160.00 | $88.00 | 55.0% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 15 | 72 | $2,232 | $21.06 | 0.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 148 | 303 | $44,813 | $14,038 | 31.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 80 | 80 | $15,364 | $8,516 | 55.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 69 | 120 | $25,068 | $7,819 | 31.2% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 39 | 39 | $3,666 | $2,673 | 72.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 51 | 51 | $969.00 | $949.62 | 98.0% |
| 90682 | Influenza vaccine, quadrivalent derived from recombinant dna | Office | 2022 | 11 | 11 | $1,034 | $753.94 | 72.9% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2022 | 18 | 18 | $1,080 | $733.65 | 67.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 32 | 74 | $2,981 | $582.54 | 19.5% |
| 0134A | Fee covid-19 vac 14 res | Office | 2022 | 14 | 14 | $630.00 | $438.62 | 69.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 74 | 96 | $960.00 | $281.43 | 29.3% |
| 81003 | Automated urinalysis test | Office | 2022 | 31 | 47 | $194.00 | $104.07 | 53.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 11 | 12 | $576.00 | $101.15 | 17.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 145 | 325 | $47,571 | $16,832 | 35.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 62 | 62 | $12,728 | $6,730 | 52.9% |
About Drake Mason, NP
Drake Mason, NP is a Diabetes Educator healthcare provider based in Monroe, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2014. The National Provider Identifier (NPI) number assigned to this provider is 1194131516.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Drake Mason, NP has received a total of $682.12 in payments from pharmaceutical and medical device companies, with $215.16 received in 2024. These payments were reported across 41 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($682.12).
As a Medicare-enrolled provider, Mason has provided services to 1,955 Medicare beneficiaries, totaling 3,468 services with total Medicare billing of $121,895. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Diabetes Educator
- Other Specialties Nurse Practitioner
- Location Monroe, UT
- Active Since 07/07/2014
- Last Updated 11/27/2023
- Taxonomy Code 163WD0400X
- Entity Type Individual
- NPI Number 1194131516
Products in Payments
- VRAYLAR (Drug) $234.22
- TRADJENTA (Drug) $40.94
- BELSOMRA (Drug) $35.14
- SHINGRIX (Biological) $32.37
- COLOGUARD DNA CAPTURE REAGENTS (Device) $31.18
- FARXIGA (Drug) $30.00
- LATUDA (Drug) $27.70
- TRULICITY (Drug) $24.56
- Auvelity (Drug) $19.74
- Ozempic (Drug) $17.65
- Kerendia (Drug) $17.14
- ZENPEP (Drug) $16.58
- JARDIANCE (Drug) $15.69
- GVOKE HYPOPEN (Drug) $15.57
- Otezla (Drug) $15.45
- TZIELD (Biological) $15.25
- IBSRELA (Drug) $14.56
- REXULTI (Drug) $14.55
- AREXVY (Drug) $14.52
- CAPLYTA (Drug) $13.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.